Assessing urinary proteins to differentiate ovarian cancer from non-cancer conditions
Official title: Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression
Run by Xiangya Hospital of Central South University · NCT06760923 · Data updated 2026-11-12
This study is testing if certain proteins in urine can help tell the difference between women with ovarian cancer and those without it.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 240 (estimated) |
| Sponsor | Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | January 7, 2025 |
| Trial ID | NCT06760923 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are female patients over 18 years old who are undergoing surgical treatment for suspected gynecological conditions.
✕Probably not a fit
Patients with a history of malignant tumors, chronic kidney disease, or those currently receiving treatment for their primary disease may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to analyze the urinary proteomic characteristics in women diagnosed with ovarian cancer compared to those without the disease. It seeks to identify differences in urinary protein composition that could assist in diagnosing ovarian cancer and monitoring disease progression. The study will evaluate whether specific urinary protein markers correlate with tumor burden in patients with ovarian cancer. By understanding these proteomic differences, the research hopes to enhance diagnostic and surveillance strategies for ovarian cancer.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools and monitoring methods for ovarian cancer, potentially allowing for earlier detection and better management of the disease.
How similar studies have gone: While the approach of using urinary proteomics for cancer diagnosis is being explored, this specific study's methodology and focus on ovarian cancer may provide novel insights into the field.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female patients in the gynecological ward for surgical treatment. * Initial diagnosis of "pelvic mass" or "malignant ascites" may be considered as ovarian cancer; Or the initial diagnosis of "ovarian cyst", "hydrosalpinx", "uterine fibroids" or "uterine adenomyosis" are considered as gynecological non-malignant diseases. * Over 18 years of age. * Voluntary participation and signing of informed consent. Exclusion Criteria: * Study participants with a prior history of malignant tumors. * Study participants with prior chronic kidney disease or renal insufficiency. * Study participants who have received or are receiving treatment for primary disease. * Study participants whose pathological diagnosis was not clear. Any patient should be excluded from the study if: * Study participants withdraw informed consent and request withdrawal. * Study participants were unable to provide a qualified urine sample. * There are situations in which the researcher considers it necessary to withdraw from the study.
Where it's running
-
Xiangya Hosipital of Central South University
Changsha, Hunan, China Recruiting
Study contacts
- Study coordinator: Yu Zhang, PhD
- Email: xyzhangyu@csu.edu.cn
- Phone: +86 0731-89753999
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rectosigmoid Lesion Excision vs. Resection in Advanced Ovarian Cancer
This study tests whether removing a rectosigmoid lesion without full bowel resection can be as safe as removing the bowel segment in women with advanced ovarian cancer.
-
Trastuzumab deruxtecan versus standard treatment for ovarian cancer that returned after PARP inhibitor therapy
This study will test whether trastuzumab deruxtecan helps people with HER2-expressing recurrent ovarian, fallopian tube, or peritoneal cancer that progressed on prior PARP inhibitor therapy compared with standard chemotherapy or bevacizumab.
-
Analysis of the ovarian (infundibulopelvic) ligament removed during ovarian cancer surgery
This project will test whether cancer in the infundibulopelvic ligament removed at surgery is linked to para‑aortic lymph node spread and outcomes in people with epithelial ovarian cancer.
-
Comprehensive pre-surgery conditioning, with or without planned preoperative cancer therapy, before major abdominal or pelvic cancer operations.
This trial will test whether a comprehensive prehabilitation program, given alone or with planned neoadjuvant therapy, helps pre-frail or frail adults with pancreatic, ovarian, kidney, or bladder cancer better tolerate major cancer surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.